ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
-
Impel NeuroPharma Announces Last Patient Enrolled in INP104 Trial for Migraine americanpharmaceuticalreview
September 05, 2019Impel NeuroPharma announced the last patient has been enrolled in "STOP-301" (Safety and Tolerability of POD-DHE), the Company's pivotal open-label Phase 3, multi-use... -
Impel NeuroPharma Closes $67.5 Million Series D Financing
firstwordpharma
December 06, 2018Impel NeuroPharma ("Impel" or the "Company"), a?Seattle-based, privately-held biotechnology company focused on developing therapies for the treatment of central nervous system ("CNS") disorders with unmet medical needs, today announced that it has complet -
Impel NeuroPharma Closes $67.5 Million Series D Financing
firstwordpharma
December 06, 2018Impel NeuroPharma ("Impel" or the "Company"), a?Seattle-based, privately-held biotechnology company focused on developing therapies for the treatment of central nervous system ("CNS") disorders with unmet medical needs, today announced that it has complet
Pharma Sources Insight January 2025
